These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 32305267

  • 1. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
    Labbate CV, Werntz RP, Galansky LB, Packiam VT, Eggener SE.
    Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
    [Abstract] [Full Text] [Related]

  • 2. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A.
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [Abstract] [Full Text] [Related]

  • 3. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ, Sheinfeld J.
    Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY.
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
    Tachibana I, Kern SQ, Douglawi A, Tong Y, Mahmoud M, Masterson TA, Adra N, Foster RS, Einhorn LH, Cary C.
    J Clin Oncol; 2022 Nov 10; 40(32):3762-3769. PubMed ID: 35675585
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J.
    J Urol; 2005 Aug 10; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [Abstract] [Full Text] [Related]

  • 11. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R.
    Eur Urol; 2013 Jun 10; 63(6):1013-7. PubMed ID: 23021090
    [Abstract] [Full Text] [Related]

  • 12. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
    Heidenreich A, Pfister D.
    Arch Esp Urol; 2012 Mar 10; 65(2):215-26. PubMed ID: 22414450
    [Abstract] [Full Text] [Related]

  • 13. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
    Speir RW, Calaway AC, Einhorn LH, Foster RS, Cary C.
    Urol Oncol; 2020 Aug 10; 38(8):687.e19-687.e23. PubMed ID: 32448503
    [Abstract] [Full Text] [Related]

  • 14. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, Sheinfeld J.
    Cancer; 2008 Feb 15; 112(4):800-5. PubMed ID: 18172902
    [Abstract] [Full Text] [Related]

  • 15. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
    Tong S, Chen M, Zu X, Li Y, He W, Lei Y, Liu W, Qi L.
    Int Urol Nephrol; 2014 Feb 15; 46(2):363-9. PubMed ID: 23996573
    [Abstract] [Full Text] [Related]

  • 16. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.
    Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia A.
    Eur Urol Oncol; 2020 Apr 15; 3(2):198-206. PubMed ID: 31272940
    [Abstract] [Full Text] [Related]

  • 17. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
    Nicolai N, Cattaneo F, Biasoni D, Catanzaro M, Torelli T, Zazzara M, Necchi A, Giannatempo P, Raggi D, Piva L, Colecchia M, Salvioni R, Stagni S.
    J Endourol; 2016 Oct 15; 30(10):1112-1119. PubMed ID: 27533924
    [Abstract] [Full Text] [Related]

  • 18. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
    Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G.
    Eur Urol; 2008 Nov 15; 54(5):1004-15. PubMed ID: 18722704
    [Abstract] [Full Text] [Related]

  • 19. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ, Bosl GJ, Motzer RJ, Bajorin DF, Stasi JP, Sheinfeld J.
    J Clin Oncol; 2007 Dec 10; 25(35):5597-602. PubMed ID: 18065732
    [Abstract] [Full Text] [Related]

  • 20. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.